Hillhouse's HHLR Increases Stake in Nvidia, Coherent in Q2 Semiconductor Push
SingTao · 2 SOURCESabout 1 hour ago3 MIN
Summary
Hillhouse Capital's基金管理平台HHLR Advisors disclosed its Q2 US equity holdings, revealing a portfolio of 35 stocks valued at approximately $832 million as of June 30 . Biotech remained the cornerstone of the portfolio, comprising over 50% of total portfolio value . The fund strategically increased positions in semiconductor and optical communication companies, adding Nvidia, Coherent, Corning, and Lumentum alongside existing holding Marvell Technology . Notably, BeiGene disappeared from the disclosed holdings, while two new names emerged: Alamar Biosciences and Odyssey Therapeutics, both companies previously backed by Hillhouse in private markets before their IPOs .
Key Points
- HHLR's total US portfolio reached $832 million across 35 stocks, with biotech representing over half of portfolio value
- Top five holdings: Legend Biotech, Futu Holdings, ArriVent, Marvell Technology, and Vipshop
- Q2 increases included Nvidia, Coherent, Corning, and Lumentum in semiconductor and optical communication sectors
- Alamar Biosciences and Odyssey Therapeutics entered the public portfolio as Hillhouse rotated private-market investments
- BeiGene was absent from the 13F filing, though this only reflects SEC-required disclosures, not the full investment scope